Erastin: Promising for Cancer and Neurological Disorders via Heme Inhibition | GlpBio
Erastin is a tiny chemical being researched for its possible application in the treatment of some cancers and neurological diseases. It was discovered in 2015 by a group of researchers from the University of Texas Southwestern Medical Centre who were investigating the impact of several chemicals on cancer cells.
Erastin works by suppressing the action of a protein called ferrochelatase, which is involved in the formation of heme, a substance required by many enzymes and proteins in the body. Erastin, by blocking ferrochelatase, can impair heme formation, potentially leading to the death of cancer cells or other aberrant cells that rely on heme for survival.
Unveil the potential of Erastin in cancer treatment, as this innovative compound holds promise in targeting and selectively inducing ferroptosis, a novel cell death pathway, offering new avenues for effective anti-cancer therapies.
Erastin has been proven to exhibit anti-tumor action in animal models of cancer, as well as neuroprotective benefits in animal models of neurological illnesses such as stroke and Alzheimer's disease. More research is needed, however, to fully understand erastin's possible therapeutic effects and to determine its safety and effectiveness in humans.
For more information, please visit here: https://www.glpbio.com/erastin.html
